The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results